Trial Profile
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Shanghai Unicar-Therapy Bio-medicine Technology
- 27 Nov 2023 Planned End Date changed from 18 Feb 2024 to 31 Dec 2025.
- 27 Nov 2023 Planned primary completion date changed from 1 Aug 2023 to 31 Dec 2024.
- 18 May 2022 Planned End Date changed from 18 Feb 2020 to 18 Feb 2024.